dc.contributor.author | Dou, Shaohua | |
dc.contributor.author | Yang, Chao | |
dc.contributor.author | Zou, Danfeng | |
dc.contributor.author | Da, Wa | |
dc.contributor.author | Masood, Muqaddas | |
dc.contributor.author | Adlat, Salah | |
dc.contributor.author | Baima, Yang-Jin | |
dc.contributor.author | Nasser, MI | |
dc.contributor.author | Li, Bin | |
dc.contributor.author | Jiang, Nan | |
dc.date.accessioned | 2022-10-19T05:59:50Z | |
dc.date.available | 2022-10-19T05:59:50Z | |
dc.date.issued | 2021-07-20 | |
dc.identifier.issn | 1011-601X | |
dc.identifier.uri | http://142.54.178.187:9060/xmlui/handle/123456789/13271 | |
dc.description.abstract | In this research, atractylenolide II (ATR II) on apoptosis, cell cycle cells via ER pathway in breast cancer (MDA-MB-231 and MCF-7) cells are assessed. The effect of ATR II on cell proliferation was detected by MTT assay. Additional flow cytometry, luciferase, the western blot were performed to detect the signaling pathway cytotoxicity of ATR II. We have also carried out autodock measurements to validate our results. Our findings showed ATR II could inhibit breast cancer cell growth by apoptosis mainly through G2/M-phase cell cycle arrest. Besides, the cytotoxicity of ATTR II on breast cancer was also correlated by the regulation of endrogen receptors and promising an anti-inflammatory activity via inhibiting NF-KB signaling pathways. Taking together, ATR II could be a potential anticancer drug for breast cancer. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi | en_US |
dc.subject | ATR II | en_US |
dc.subject | apoptosis | en_US |
dc.subject | ER/NF-KB | en_US |
dc.subject | G2/M | en_US |
dc.subject | autodock | en_US |
dc.title | Atractylenolide II induces cell cycle arrest and apoptosis in breast cancer cells through ER pathway | en_US |
dc.type | Article | en_US |